AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Likewise, many PI3K/AKT/mTOR pathway inhibitors, including those which have received FDA approval, such as PI3K inhibitors (Idelalisib, Copanlisib, and Duvelisib) and mTOR inhibitors (Everolimus, Sirolimus, and Temsirolimus), have been studied as potential treatments against TKI-resistant CML, and active pre-clinical investigation is ongoing (Figure 3 and Table 2) [67].